add site
services
publishers
database
health videos
toolbar
stats
live show
health store
more stuff
JOIN/LOGIN
| advertise add site services publishers database health videos
| | about toolbar stats live show health store more stuff JOIN/LOGIN |
| Health World US Business Political Technology Entertainment Sports Popular |
Investigational Oral Androgen Receptor Antagonist Shows Promising Antitumour ...DG News - - Nov 30, 2009 BARCELONA, Spain -- November 30, 2009 -- The investigational oral androgen receptor antagonist MDV3100 shows promising antitumour activity ... New Compounds, Novel Applications EvaluatedPsychiatric Times - - 4 hours ago A phase 2 trial with a dopamine D 3 /D 2 receptor antagonist caripra-zine (RGH-188, Forest Laboratories) yielded encouraging results in patients with ... Parkinson's X-rayspectroscopyNOW.com - 18 hours ago ... the solution to treating the symptoms of such disorders is not necessarily based on the simple administration of a receptor agonist or antagonist. ... CombinatoRx Oncology Programs to Be Highlighted at ASH 2009WELT ONLINE - Nov 24, 2009 CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that two abstracts highlighting data on its A2A and Beta-2 Adrenergic Receptor Agonist oncology ... CombinatoRx Oncology Programs to Be Highlighted at ASH 2009 Earthtimes (press release) OPKO Health acquires neurokinin-1 receptor antagonist from Schering-PloughTrading Markets (press release) - Nov 12, 2009 Rolapitant, a neurokinin-1 (NK-1) receptor antagonist, is used for the prevention of nausea and vomiting related to cancer chemotherapy and surgery. ... Opko Health acquires emesis drug compounds from Schering-Plough Trading Markets (press release) A Selective Endothelin-Receptor Antagonist to Reduce Blood Pressure in ...Cardiosource - Nov 20, 2009 Study Question: What is the blood pressure-lowering effect of the new vasodilatory, selective endothelin type A antagonist, darusentan, in patients with ... New findings in life sciences described from Merck & Company, Inc.Behavioral Health Central (blog) - Nov 23, 2009 Specifically, we characterized the effects of coadministering submaximally effective doses of the 5-HT2A receptor antagonist M100907 (0.2 mg/kg) and the ... ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at ...PR Newswire (press release) - Nov 25, 2009 ... were presented today in a poster titled "PROTECT-1 Study of Intestine-Specific Chemokine Receptor Antagonist CCX282-B (TRAFICET-EN) in Crohn's Disease" ... ChemoCentryx Inc reports positive results from PROTECT-1 study for Traficet-EN ... Trading Markets (press release) Platelet Inhibition With Cangrelor in Patients Undergoing PCICardiosource - Nov 17, 2009 Study Question: What is the benefit of cangrelor, a reversible adenosine diphosphate (ADP) receptor antagonist, in patients undergoing percutaneous coronary ... Cangrelor — A Champion Lost in Translation? New England Journal of Medicine (subscription) Patient enrollment completed for first of two Phase 3 trials for SCH 530348 ...Monthly Prescribing Reference - Nov 13, 2009 Merck announced the completion of patient enrollment for its Phase 3 Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic ... Merck enrolls patients in late-stage trial for heart attack-preventing drug Drug Store News (blog) | How to call the show... 1) Make sure the show is live (see graphic above). 2) Dial 724-444-7444. 3) Enter Call ID# 27566 when prompted. 4) Follow the phone prompts to join the call. Would you like to be a special guest on the show? Send us an email which includes your contact information and the topic(s) that you would like to discuss. Listen to past shows featuring special guests...  Bernard von NotHaus (Liberty Dollar)Aubrey de Grey, PhDDr. Amanuel Sima, MDDr. Bard Levey, DDSNeal AdamsRobin Scovill (director)Richard Diaz (author)Dr. Kaayla T. Daniel, CCNChana de Wolf, (cryonics researcher)Dr. Mary Ruwart (author & scientist)Richard Diaz (author)Dr. Jason Helliwell, OB/GYN |
| ↑ top of page ↑ | about thumbshots |
